Consensus Review of Optimal Perioperative Care in Breast Reconstruction: Enhanced Recovery after Surgery (ERAS) Society Recommendations.
Claire Temple-Oberle, Melissa A Shea-Budgell, Mark Tan...
https://pubmed.ncbi.nlm.nih.gov/28445352/Actively Recruiting
Led by Huazhong University of Science and Technology · Updated on 2026-03-13
60
Participants Needed
1
Research Sites
4 weeks
Total Duration
Researchers are studying the pain-relief effects of liposomal bupivacaine plus bupivacaine compared to ropivacaine for Pericapsular Nerve Group PENG block in patients undergoing hip replacement surgery. The trial aims to determine if liposomal bupivacaine plus bupivacaine provides better pain control, longer duration of relief, reduced opioid use, and higher patient satisfaction while monitoring safety. This is a randomized, double-blind, active-controlled Phase 4 study sponsored by Huazhong University of Science and Technology. Participants receive either liposomal bupivacaine plus bupivacaine or ropivacaine as a local anesthetic for the PENG block under ultrasound guidance. All undergo hip replacement surgery under spinal anesthesia. The study compares analgesic efficacy, pain relief duration, opioid consumption, and safety profiles between the two interventions within 72 hours after surgery. During the trial, pain intensity, opioid use, and complications are assessed multiple times within 72 hours following surgery. Researchers also track time to first rescue analgesic, incidence of complications or adverse events up to 90 days post-surgery, and the duration of hospital stay for about one year. The main outcome measured is overall opioid consumption within 72 hours after surgery, with safety and patient satisfaction also evaluated throughout the study period.
CONDITIONS
Bupivacaine Liposome Plus Bupivacaine or Ropivacaine for Pericapsular Nerve Group Block in Hip Arthroplasty (PENG)
X
Xijian KE, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Huazhong University of Science and Technology
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 72 hours post-surgery
Participants receive a pericapsular nerve group (PENG) block with either liposomal bupivacaine plus bupivacaine or ropivacaine during hip replacement surgery to manage postoperative pain.
Multiple assessments within 72 hours after surgery
Duration - Up to 1 year after surgery
Participants are monitored for complications or adverse events and their hospital stay duration is recorded.
Assessments at 90 days and through study completion (about 1 year)
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Claire Temple-Oberle, Melissa A Shea-Budgell, Mark Tan...
https://pubmed.ncbi.nlm.nih.gov/28445352/Laura Girón-Arango, Philip W H Peng, Ki Jinn Chin...
https://pubmed.ncbi.nlm.nih.gov/30063657/Gregg Nelson, Jamie Bakkum-Gamez, Eleftheria Kalogera...
https://pubmed.ncbi.nlm.nih.gov/30877144/Mary Ellen McCann
https://pubmed.ncbi.nlm.nih.gov/33433621/Timothy J P Batchelor, Neil J Rasburn, Etienne Abdelnour-Berchtold...
https://pubmed.ncbi.nlm.nih.gov/30304509/Joseph C Carmichael, Deborah S Keller, Gabriele Baldini...
https://pubmed.ncbi.nlm.nih.gov/28682962/Huazhong University of Science and Technology
Lead Sponsor